Massive Zantac Product Liability Litigation Advances After Initial Settlements

GlaxoSmithKline will continue to defend itself against all claims alleging ranitidine increased the risk of cancer. Four generic firms reach settlements in the first case that had been scheduled for trial. GSK, Sanofi and Pfizer could pay $1bn-$2bn each in potential settlements, an analyst predicts.

Zantac
The first trial in the Zantac product liability litigation is set to begin this month • Source: Shutterstock

More from Drug Safety

More from Pink Sheet